I am by no means a legal expert, I am thinking that seeing that Elanco hold the composition of matter patents until 2022 or 23/2024 or when ever it is and we have no agreements or options in place to enable us to commercially develop an anti-viral MPL-based product against SARS CoV2 or COVID-19, we have bugger all chance of getting any grant money because we have no legal right to MPL until Elanco's patents run their course.
On another note a little while back I took a swipe at Dr Richard Mollard.
Dr Richard Mollard is the Chief Scientific Officer of PharmAust Limited and the Chief Executive Officer of subsidiary company Pitney Pharmaceuticals Pty Limited.
In his rolls as the CSO of PharmAust and CEO of Pitney I would suggest that he would have been instrumental in the negotiating the testing at WEHI and 360 in Australia and Leiden in Holland at nominal cost and also negotiating the $890 odd grand for testing on MND. Definitely pulling his weight . Dr Mollard if you are a follower here please accept my apology/retraction.
Good luck to all.
Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-120
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |